Amyloid-related imaging abnormality edema is a known side effect of anti-amyloid monoclonal antibody treatments, such as Leqembi and donanemab Kisunla.
Data from nearly 9.9 million participants were included in the team’s final analysis. The group emphasized the important role governments can play in trying to reverse the world's reliance on these products.